Prostate cancer tends to metastasize to bones as opposed to soft tissue and other organs. We have no idea why it does have a preference for bone, but it does. Developing bone metastases in prostrate cancer is a very strong negative prognostic indicator. Prostate cancer’s tendency to favor bone over soft tissue causes significant morbidity [...]
Researchers at Queen’s University in Belfast along with the Belfast Trust are conducting a clinical trial evaluating the combination of two radiotherapy treatments, Radium 223 and Pelvic Radiation using Volumetric Modulated Arc Therapy (VMAT) in men with bone positive advanced prostate cancer. The trial, being called ADRRAD trial, involves combining androgen deprivation therapy (ADT) along [...]
Radium-223 (Xofigo) is a drug for men with castrate resistant metastatic prostate cancer (mCRCP) who have multiple bone metastases. Radium-223 selectively targets bone metastases by mimicking calcium, which is attracted to the bone, especially to the fast growing areas of the tumor in the bone. It emits an alpha-emitting dose of radiation, which is mostly contained [...]
Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]
Most people don't know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY. Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available? The DOD PCRP is directly [...]